Literature DB >> 17222587

Complementary and alternative medicine in hepatology: review of the evidence of efficacy.

Sumita Verma1, Paul J Thuluvath.   

Abstract

There is an increase in the use of complementary and alternative medicine (CAM), especially herbal therapy, among patients with liver disease. The most commonly used herbal agent is silymarin. In animal models, many of the commonly used agents have shown anti-inflammatory and antifibrotic effects. Although many human studies have shown improvements in subjective symptoms (well being) and liver biochemistry, there are no convincing data to suggest a definite histologic and/or virologic improvement with most of these agents. Poorly designed studies, heterogeneous patient populations, lack of standardized preparations, and poorly defined nonobjective end points may partly explain the conflicting reports in the literature. Hepatotoxicity and drug interactions are common with many herbal medications, and therefore physicians need to be cognizant of known or occult use of CAM by their patients. Only well-designed, randomized, controlled trials will be able to ascertain whether CAM has any role in the management of patients with acute or chronic liver diseases. Until such time, the use of CAM cannot be recommended as a therapy for patients with liver disease.

Entities:  

Mesh:

Year:  2007        PMID: 17222587     DOI: 10.1016/j.cgh.2006.10.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  19 in total

Review 1.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

Review 2.  Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.

Authors:  Enoche F Oga; Shuichi Sekine; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-04       Impact factor: 2.441

3.  Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum.

Authors:  Jiabo Wang; Zhijie Ma; Ming Niu; Yun Zhu; Qingsheng Liang; Yanling Zhao; Jingyuan Song; Zhaofang Bai; Yaming Zhang; Ping Zhang; Na Li; Yakun Meng; Qi Li; Lushan Qin; Guangju Teng; Junling Cao; Baosen Li; Shilin Chen; Yonggang Li; Zhengsheng Zou; Honghao Zhou; Xiaohe Xiao
Journal:  Front Med       Date:  2015-10-12       Impact factor: 4.592

Review 4.  In the clinic. Hepatitis C.

Authors:  Janice H Jou; Andrew J Muir
Journal:  Ann Intern Med       Date:  2008-06-03       Impact factor: 25.391

5.  Complementary and alternative medicines for hepatic disease.

Authors:  Leonard B Seeff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

6.  Potential of Aucklandia Lappa Decne Ethanolic Extract to Trigger Apoptosis of Human T47D and Hela Cells

Authors:  S S Hasson; A S H Al-Shubi; J Z Al-Busaidi; M S Al-Balushi; F L Hakkim; L Rashan; G M Aleemallah; A A Al-Jabri
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27

7.  Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.

Authors:  N D Freedman; T M Curto; C Morishima; L B Seeff; Z D Goodman; E C Wright; R Sinha; J E Everhart
Journal:  Aliment Pharmacol Ther       Date:  2010-11-02       Impact factor: 8.171

8.  Curcumin protects against concanavalin A-induced hepatitis in mice through inhibiting the cytoplasmic translocation and expression of high mobility group box 1.

Authors:  Chuan-tao Tu; Qun-yan Yao; Bei-li Xu; Shun-cai Zhang
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

9.  Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Authors:  Michael W Fried; Victor J Navarro; Nezam Afdhal; Steven H Belle; Abdus S Wahed; Roy L Hawke; Edward Doo; Catherine M Meyers; K Rajender Reddy
Journal:  JAMA       Date:  2012-07-18       Impact factor: 56.272

10.  Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.

Authors:  Yong-An Ye; Xiao-Ke Li; Da-Qiao Zhou; Xiao-Ling Chi; Qin Li; Li Wang; Bing-Jiu Lu; De-Wen Mao; Qi-Kai Wu; Xian-Bo Wang; Ming-Xiang Zhang; Jing-Dong Xue; Yong Li; Wei Lu; Jian-Chun Guo; Feng Jiang; Xin-Wei Zhang; Hong-Bo Du; Xian-Zhao Yang; Hui Guo; Da-Nan Gan; Zhi-Guo Li
Journal:  Chin J Integr Med       Date:  2018-09-12       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.